Eliquis (apixaban) belongs to a class of new anticoagulants known as Factor Xa inhibitor, which also includes the medications Pradaxa and Xarelto. It was developed by Pfizer and Bristol-Myers Squibb, and has been aggressively promoted in direct-to-consumer advertisements.
Approved by the FDA in December 2012, Eliquis is prescribed to reduce the risk of blood clots. It is promoted as a superior replacement for Coumadin, sold generically as Warfarin, which has been the leading anticoagulant for decades. However, users may face a substantial risk of suffering severe injury or wrongful death from bleeding problems while using Eliquis, which was not adequately disclosed on the drug label.
Shortly after the medication was introduced, reports of Eliquis bleeding problems began to surface, raising similar concerns to those linked to Xarelto side effects and Pradaxa side effects.
While doctors are able to quickly reverse the effects of warfarin if bleeding develops, there was no approved antidote for Eliquis, Pradaxa or Xarelto at the time these new medications were introduced.
Due to a lack of adequate warnings provided by the drug makers, many individuals have suffered severe bleeding complications, where doctors were unable to stop blood loss. This uncontrollable bleeding may result in:
- Extended Hospitalization
- Intensive Care Treatment (ICU)
- Blood Transfusions
- Wrongful Death
Recent studies have also raised questions about the claims by the drug makers that Eliquis does not require blood monitoring, as it is possible such recommendations may have helped doctors identify individuals who may be at risk of bleeds on Eliquis.
REVIEW AN ELIQUIS CASE